Resources

Interview with Marcel van Duin, Senior Director, Reproductive Health & Endocrinology Research.  Time to Unite! – A Greater Medicon Valley 2020 (page 2)
http://np.netpublicator.com/netpublication/n39030597

Maybauer MO, Maybauer DM, Enkhbaatar P, Laporte R, Wisniewska H, Traber LD, Lin C, Fan J, Hawkins HK, Cox RA, Wisniewski K, Schteingart CD, Landry DW, Riviere PJ, Traber DL.  The selective vasopressin type 1a receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis*.  Crit. Care. Med.  2014.  Jul;42(7):e525-33

Wisniewski K, Alagarsamy S, Galyean R, Tariga H, Thompson D, Ly B, Wisniewska H, Qi S, Croston G, Laporte R, Riviere P, Schteingart, CD.  New, Potent, and Selective Peptidic Oxytocin Receptor Agonists.  J. Med. Chem.  2014.  Jun 26;57(12):5306-17

Wisniewski K, Finnman J, Flipo M, Galyean R, Schteingart CD.  On the mechanism of degradation of oxytocin and its analogues in aqueous solution.  Biopolymers Pep. Sci.  2013. Jul;100(4):408-21

Marir R, Virsolvy A, Wisniewski K, Mion J, Haddou D, Galibert E, Meraihi Z, Desarménien MG, Guillon G.  Pharmacological characterization of FE 201874, the first selective high affinity rat V1A vasopressin receptor agonist.  Br. J. Pharmacol. 2013. 100 (278-292)

Ferdyan N, Qi S, Srinivasan K.  Studying Plasma Protein Binding of Peptide Drug Candidates: Comparison of the Millipore Ultrafiltration Devices.  National Biotechnology Conference.  2012

Leveque M, Beaufrand C, Alexander R, Riviere P, Theodorou V, Bueno L.  Comparative colonic epithelial cell repair by human defensins an chemokines: Role of chemokine receptor 6.  Digestive Disease Week. 2012

Qi S, Ferdyan N, Srinivasan K, Pilato V, Schteingart C.  Studying Ultracentrifugation as an Approach for Measurement of Plasma Protein Binding of Peptidic Drug Candidates.  National Biotechnology Conference.  2012

Rehberg S, Enkhbaatar P, Rehberg J, La E, Ferdyan N, Qi S, Wisniewski K, Traber LD, Schteingart CD, Rivière PJ, Laporte R, Traber DL.  Unlike arginine vasopressin, the selective V1a receptor agonist FE 202158 does not cause procoagulant effects by releasing von Willebrand factor.  Crit Care Med. 2012 Jun;40(6):1957-60

Wisniewski K, Finnman J, Flipo M, Galyean R, Schteingart C.  On the Mechanism of Degradation of Oxytocin and its Analogues in Aqueous Solutions – Part II.  32nd European Peptide Symposium.  2012

Dunn M.  Timing of patent filing and market exclusivity.  Nat Rev Drug Discov.  2011 Jul 1;10(7):487-8

Hargrove D, Alagarsamy S, Qi S, Srinivasan K, Croston G, Laporte R, Sueiras-Diaz J, Wisniewski K, Hartwig J, Wisniewski H, Lu M, Posch A, Schteingart C, Riviere P.  Pharmacological characterization of FE 203799, a novel long acting peptide analog of glucagon-like peptide-2 (GLP-2).  Digestive Disease Week.  2011

Laporte R, Kohan A, Heitzmann J, Wisniewska H, Toy J, La E, Tariga H, Alagarsamy S, Ly B, Dykert J, Qi S, Wisniewski K, Galyean R, Croston G, Schteingart CD, Rivière PJ.  Pharmacological characterization of FE 202158, a novel, potent, selective, and short-acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension.  J Pharmacol Exp Ther. 2011 Jun;337(3):786-96

Qi S, Srinivasan K, Hargrove D, Hartwig J, Ferdyan N, Alagarsamy S, Croston G, Laporte R, Sueiras-Diaz J, Wisniewski K, Wisniewski H, Lu M, Posch A, Schteingart C. Riviere P.  Bioanalysis and Pharmacokinetic Profile of FE 203799: A Novel Glucagon-Like Peptide-2 (GLP-2) Long Acting Peptide Agonist.  AAPS. 2011

Sonesson A, Koechling W, Stalewski J, Tankó LB, Rasmussen BB.  Metabolite profiles of degarelix, a new gonadotropin-releasing hormone receptor antagonist, in rat, dog, and monkey.  Drug Metab Dispos. 2011 Oct;39(10):1895-903

Srinivasan K, Qi S, Hargrove D, Hartwig J, Ferdyan N, Alagarsamy S, Croston G, Laporte R, Sueiras-Diaz J, Wisniewski K, Wisniewski H, Lu M, Posch A, Schteingart C, Riviere P.  Pharmacokinetic Profile of  203799: A Novel Long Acting Peptide Agonist of Glucagon-Like Peptide-2 (GLP-2).  American Peptide Symposium.  2011

Wisniewski K, Galyean R, Tariga H, Alagarsamy S, Croston G, Heitzmann J, Kohan A, Wisniewska H, Laporte R, Rivière PJ, Schteingart CD.  New, potent, selective, and short-acting peptidic V1a receptor agonists.  J Med Chem. 2011 Jul 14;54(13):4388-98

Wisniewski K, Finnman J, Flipo M, Galyean R, Schteingart C.  On the Mechanism of Degradation of Oxytocin and its Analogues in Aqueous Solutions.  American Peptide Symposium.  2011

Wisniewski K, Sueiras-Diaz J, Jiang G, Galyean R, Lu M, Croston G, Hargrove D, Qi S, Srinivasan K, Hartwig J, Ferdyan N, Wisniewski H, Laporte R, Alagarsamy S, Schteingart C, Riviere P.  Synthesis and Pharmacological Characterization of Novel, Potent and Low Clearance GLP-2 Analogues.  American Peptide Symposium.  2011

Wisniewski K, Galyean R, Schteingart C, Tariga H, Croston G, Alagarsamy S, Riviere P.  Synthesis and in vitro Characterization of New, Potent and Selective Oxytocin Receptor Agonists.  European Peptide Symposium.  2010

Huhtaniemi I, White R, McArdleCA, Persson BE.  Will GnRH antagonists improve prostate cancer treatment? Trends Endocrinol Metab. 2009 Jan;20(1):43-50.

Laporte R, Wisniewski K, Schteingart C, Traber D, Landry D, Riviere P.  Vasopressin V1a Receptor Agonists in Vasodilatory Shock: From Bedside to Bench and Back.  World Congress on Neurohypophyseal Hormones.  2009

Rehberg S, Enkhbaatar P, Laporte R, Rehberg J, La E, Wisniewski K, Ferdyan N, Qi S, Traber L, Schteingart C, Riviere P, Traber D.  The selective V1a receptor agonist FE 202158 does not cause von Willebrand factor release in sheep unlike arginine vasopressin.  Sepsis Forum.  2009

Schteingart C, Jiang G, Gaylean R, Stalewski J, Rivier J, White R, Schwach G.  Discovery of Degarelix, a Self-Depoting GnRH Antagonist with Long Duration of Action.  American Peptide Symposium. 2009

Wisniewski K, Galyean R, Taki H, Alagarsamy S, Croston G, Laporte R, Schteingart C, Riviere P.  Synthesis and in vitro pharmacological profile of potent and selective peptidic V1a receptor agonists.  American Peptide Symposium. 2009

Alagarsamy  S, Rey S, La E, Taki H, Tam H, Sharma N, Croston G, Riviere P, Verbalis J.  Oxytocin Induces Antidiuresis and Hyponatremia through Activation of Vasopressin V2 Receptors at Physiologically Relevant Concentrations.  Endocrine Society Annual Meeting.  2008

Gugger M, White R, Song S, Waser B, Cescato R, Rivière P, Reubi JC.  GPR87 is an overexpressed G-protein coupled receptor in squamous cell carcinoma of the lung.  Dis Markers. 2008;24(1):41-50

Hauser B, Asfar P, Calzia E, Laporte R, Georgieff M, Radermacher P.  Vasopressin in vasodilatory shock: is the heart in danger? Crit Care. 2008;12(2):132

Laporte R, Russell J, Landry D, Riviere P.  The selective V1a receptor agonist FE 202158 reverses platelet activating factor (PAF)-induced hypotension, vascular leak, impaired tissue perfusion, and mortality in rats.  International Symposium on Intensive Care and Emergency Medicine (ISICEM),Brussels.  2008

Lenz J, Laporte R, Schteingart C, Riviere P, Curry F.  Vasopressin V2  receptor (V2R)-mediated potentiation of platelet activating factor (PAF)-induced increase in rat mesentery venular microvessel permeability.  Federation of American Societies for Experimental Biology.  2008

Vanderah TW, Largent-Milnes T, Lai J, Porreca F, Houghten RA, Menzaghi F, Wisniewski K, Stalewski J, Sueiras-Diaz J, Galyean R, Schteingart C, Junien JL, Trojnar J, RivièrePJ.  Novel D-amino acid tetrapeptides produce potent antinociception by selectively acting at peripheral kappa-opioid receptors.  Eur J Pharmacol. 2008 Mar 31;583(1):62-72

Wisniewski K, Galyean R, Schteingart C, Taki H, Alagarsamy S, Croston G, Heitzmann J, Kohan A, Wisniewski H, Laporte R, Riviere P.  New, all non-aromatic vasopressin v1a receptor agonists.  European Peptide Symposium. 2008

Yea CM, Allan CE, Ashworth DM, Barnett J, Baxter AJ, Broadbridge JD, Franklin RJ, Hampton SL, Hudson P, Horton JA, Jenkins PD, Penson AM, Pitt GR, Rivière P, Robson PA, Rooker DP, Semple G, Sheppard A, Haigh RM, Roe MB.  New benzylureas as a novel series of potent, nonpeptidic vasopressin V2 receptor agonists.  J Med Chem. 2008 Dec 25;51(24):8124-34

Princivalle M, Broqua P, White R, Meyer J, Mayer G, Elliott L, Bjarnason K, Haigh R, Yea C.  Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.  J Pharmacol Exp Ther. 2007 Mar;320(3):1113-8

Princivalle M, Broqua P, White R, Meyer J, Mayer G, Elliott L, Bjarnason K, Haigh R, Yea C.  Degarelix, a GnRH receptor blocker, mimics the effect of surgical castration better than triptorelin and leuprolide in the Dunning tumour model.  EMUC. 2007

Samant MP, White R, Hong DJ, Croston G, Conn PM, Janovick JA, RivierJ.  Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized derivatives.  J Med Chem. 2007 May 3;50(9):2067-77

White R, Schwach G, Schteingart C.  Degarelix, a unique, sustained-release depot GnRH receptor blocker with a long duration of action.  EMUC.  2007

Wisniewski K, Galyean R, Taki H, Alagarsamy S, Croston G, Laporte R, Schteingart C, Riviere P.  Synthesis and in vitro pharmacological profile of potent and selective peptidic V1a receptor agonists.  American Peptide Symposium.  2007

Hoffmaster S, Croston G, Alexander R.  Multiplexing a high throughput screen (HTS) for two GPCRs improves the selection of receptor-selective hits.  Society for Biomolecular Screening.  2006

Samant MP, Hong DJ, Croston G, Rivier C, RivierJ.  Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III.  J Med Chem. 2006 Jun 15;49(12):3536-43

Taki H, Kroncke D, Karg J, Croston G, Alagarsamy S.  PocketTips™ Application For High Throughput Screening Using FLIPR384®.  Society for Biomolecular Screening.  2006

Wang YC, Lu M, Riviere P, Croston G.  In Vitro Characterization of Cannabinoid Receptor CB2 Agonists.  International Conference of the Inflammation Research Association. 2006

Wisniewski K, Schteingart C, Nilsson A.  Tritium labeling of barusiban (FE 200440), a potent oxytocin antagonist.  European Peptide Symposium. 2006

Wisniewski K, Schteingart C, Nilsson A.  Tritium labeling of barusiban (FE 200440), a potent oxytocin antagonist.  European Peptide Symposium.  2006

Alagarsamy S, Taki H, Miampamba M, Laporte R, Wisniewski K, Galyean R, Trojnar J, Schteingart C, Riviere P, Croston G.  In vitro and in vivo activity of terlipressin and putative metabolites.  American Physiological Society Conference. 2005

Croston G, Taki H, Qi S, White R, Stalewski J, Horton J, Franklin R, Cook K, Akinsanya K, Riviere P, Trojnar J, Alagarsamy S.  Human vasopressin V2 receptor polymorphic variant responses to peptide and non-peptide agonists.  American Physiological Society Conference. 2005

Laporte R, Alagarsamy S, Croston G, Barberis C, Lopez-Bernal A, Novy J, Wisniewski K, Nilsson A, Schteingart C, Trojnar J, Melin P, Riviere J.  Barusiban (FE200440): A new potent, selective and long lasting peptidic oxytocin antagonist.  SGI InternationalSummit. 2005

Samant MP, Miller C, Hong DJ, Koerber SC, Croston G, Rivier CL, Rivier JE.  Synthesis and biological activity of GnRH antagonists modified at position 3 with 3-(2-methoxy-5-pyridyl)-alanine.  J Pept Res. 2005 Feb;65(2):284-91

Samant MP, Gulyas J, Hong DJ, Croston G, Rivier C, Rivier J.  Synthesis, in vivo and in vitro biological activity of novel azaline B analogs.  Bioorg Med Chem Lett. 2005 Jun 2;15(11):2894-7

Samant MP, Hong DJ, Croston G, Rivier C, RivierJ.  Novel gonadotropin-releasing hormone antagonists with substitutions at position 5.  Biopolymers. 2005;80(2-3):386-91

Slusarz MJ, Gieldon A, Slusarz R, Trojnar J, Meadows R, Ciarkowski J.  Study of New Oxytocin Antagonist Barusiban (Fe200 440) Affinity Toward Human Oxytocin Receptor Versus Vasopressin V1a and V2 Receptors – Molecular Dynamics Simulation in POPC Bilayer.  QSAR Comb. Sci 2005 24(603-610)

Taki H, Alagarsamy S, Croston G, Jiang G, Stalewski J, Galyean R, Schteingart C, Nilsson A, Trojnar J, Wisniewski K.  In vitro activity and synthesis of heptapeptide oxytocin antagonists.  American Physiological Society Conference. 2005

Wang YC, Hoffmaster S, Muneyyirci-Delale O, Riviere P, Akinsanya K.  G-Protein Coupled Receptor Gene Expression Profiling in Human Uterine Leiomyoma and Myometrium.  Endocrine Society Annual Meeting. 2005

Wisniewski K, Alagarsamy S, Taki H, Miampamba M, Laporte R, Galyean R, Croston G, Schteingart C, Riviere P, Trojnar J.  Synthesis and biological activity of terlipressin and its putative metabolites.  American Peptide Symposium.  2005

Wisniewski K, Alagarsamy S, Taki H, Miampamba M, Laporte R, Galyean R, Croston G, Schteingart C, Riviere P, Trojnar J.  Synthesis and biological activity of terlipressin and its putative metabolites.  American Peptide Symposium.  2005

Woznica I, Tsomaia N, Ruchala P, Thomas B, Mierke D, Chorev M, Alexander R, Sueiras-Diaz J, Schteingart C, Akinsanya K, Riviere P, Rosenblatt M, Wittelsberger A.  A Structure-Activity Relationship Study of PTH Analogs Modified in Position 5.  ASBMR Annual Meeting. 2005

Zagha E, Ozaita A, Chang SY, Nadal MS, Lin U, Saganich MJ, McCormack T, Akinsanya KO, Qi SY, Rudy B.  DPP10 Modulates Kv4-mediated A-type Potassium Channels.  J Biol Chem. 2005 May 13;280(19):18853-61

RivierePJ.  Peripheral kappa-opioid agonists for visceral pain.  Br J Pharmacol. 2004 Apr;141(8):1331-4

Wisniewski K, Jiang G, Stalewski J, Galyean R, Alagarsamy S, Taki H, Schteingart C, Riviere P, Croston G, Trojnar J, Nilsson A.  Synthesis and in vitro activity of heptapeptide oxytocin antagonists.  European Peptide Symposium. 2004

Adams BA, Tello JA, Erchegyi J, Warby C, Hong DJ, Akinsanya KO, Mackie GO, Vale W, Rivier JE, Sherwood NM.  Six novel gonadotropin-releasing hormones are encoded as triplets on each of two genes in the protochordate, Cionaintestinalis.  Endocrinology. 2003 May;144(5):1907-19

Wisniewski K.  On-Resin Formation of the GlyY[CH2NH]Aaa Type Reduced Peptide Bond by Mitsunobu Alkylation.   European Peptide Symposium.  2002

Jiang G, Stalewski J, Galyean R, Dykert J, Schteingart C, Broqua P, Aedi A, Aubert ML, Semple G, Robson P, Akinsanya K, Haigh R, Riviere P, Trojnar J, Junien JL, RivierJE.  GnRH Antagonists: A New Generation of Long Acting Analogues Incorporating p-Ureido-phenylalanines at Positions 5 and 6.  J Med Chem. 2001 Feb 1;44(3):453-67

Wisniewski K, Sueiras-Diaz J, Schteingart C, Galyean R, Houghten R, Vanderah T, Porreca F, Riviere P, Junien JL, Trojnar, J.  Long Acting, Selective, Peripheral Kappa Agonists.  European Peptide Symposium. 2000

Riviere P, Vanderah T, Houghten R, Schteingart C, Trojnar J, Lai J, Porreca F, Junien J.  Novel, D-Amino acid tetrapeptides demonstrate unprecedented k-opioid receptor selectivity and antinociception.  International Narcotics Research Conference.  1999